A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma

Cancer Research

Volumn 71, Issue 11, 2011, Pages 3841-3851

  Shohet, Jason M ^a   Ghosh, Rajib ^b   Coarfa, Cristian ^a   Ludwig, Andrew ^a   Benham, Ashley L ^b   Chen, Zaowen ^a   Patterson, Danielle M ^a   Barbieri, Eveline ^a   Mestdagh, Pieter ^c   Sikorski, Denae N ^a   Milosavljevic, Aleksandar ^a   Kim, Eugene S ^a   Gunaratne, Preethi H ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b University of Houston   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; MICRORNA; MICRORNA 103 1; MICRORNA 103 2; MICRORNA 18A; MICRORNA 191; MICRORNA 19A; MICRORNA 19B 1; MICRORNA 20A; MICRORNA 302A; MICRORNA 302B; MICRORNA 302C; MICRORNA 302D; MICRORNA 340; MICRORNA 367; MICRORNA 425; MICRORNA 548D 1; MICRORNA 558; MICRORNA 589; MICRORNA 591; MICRORNA 629; MICRORNA 636; MICRORNA 643; MICRORNA 661; MICRORNA 663; MICRORNA 7 1; MICRORNA 877; MICRORNA 92A 1; MICRORNA 933; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE REPRESSION; GENOME; HOST; INTRON; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYC; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SIMULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, TUMOR SUPPRESSOR; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 79957919750     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4391     Document Type: Article

References (50)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
2. Croce CM. Oncogenes and cancer. N Engl J Med 2008;358:502-11. (Pubitemid 351185806)
3. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101:12664-9. (Pubitemid 39122080)
4. Johnsen JI, Kogner P, Albihn A, Henriksson MA. Embryonal neural tumours and cell death. Apoptosis 2009;14:424-38.
5. Borgdorff V, Lleonart ME, Bishop CL, Fessart D, Bergin AH, Overhoff MG, et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene 2010;29:2262-71.
6. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010;294971-9.
7. Li H, Bian C, Liao L, Li J, Zhao RC. miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 2011;126:565-75.
8. Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008;27:5204-13.
9. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-8.
10. Kasinski AL, Slack FJ. Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling. Curr Opin Mol Ther 2010;12:147-57.
11. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-56.
12. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, Vermeulen J, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010;29:1394-404.
13. Northcott PA, Fernandez-LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009;69:3249-55.
14. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204: 179-87. (Pubitemid 38167721)
15. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-97.
16. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95. (Pubitemid 27234938)
17. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2010;70:1377-88.
18. Mestdagh P, Boström AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010;40:762-73.
19. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, , et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102:731-6. (Pubitemid 40282734)
20. www.illumina.com. Illumina Sequencing Applications Platform. 2011 [cited. 2011]. Available from: http://www.illumina.com/.
21. Coarfa C, Milosavljevic A. Pash 2.0: scaleable sequence anchoring for next-generation sequencing technologies. Pac Symp Biocomput 2008;102-13.
22. Ahn HW, Morin RD, Zhao H, Harris RA, Coarfa C, Chen ZJ, et al. MicroRNA transcriptome in the newborn mouse ovaries determined by massive parallel sequencing. Mol Hum Reprod 2010;16:463-71.
23. Go. Genboree website [Internet]. Bioinformatics Research Laboratory, Baylor College of Medicine; 2011 [updated 2010 Oct; cited 2010 Nov]. Available from: http://www.genboree.org/java-bin/login.jsp.
24. Vasudevan SA, Shang X, Chang S, et al. Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. Mol Cancer Ther 2009;8:2478-89.
25. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006;5:2358-65.
26. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15:5560-8.
27. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91. (Pubitemid 39330995)
28. Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell 2010;40:205-15.
29. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RTqPCR data normalization. Genome Biol 2009;10:R64.
30. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: a review. Am J Med Genet C Semin Med Genet 2011;157:3-32.
31. Sawada S, Kinjo T, Makishi S, Tomita M, Arasaki A, Iseki K, et al. Downregulation of citrin, a mitochondrial AGC, is associated with apoptosis of hepatocytes. Biochem Biophys Res Commun 2007;364:937-44. (Pubitemid 350087891)
32. Sippel M, Rajala R, Korhonen L, Bornhauser B, Sokka AL, Naito M, et al. Dexamethasone regulates expression of BRUCE/Apollon and the proliferation of neural progenitor cells. FEBS Lett 2009; 583:2213-7.
33. Aharinejad S, Andrukhova O, Lucas T, Zuckermann A, Wieselthaler G, Wolner E, et al. Programmed cell death in idiopathic dilated cardiomyopathy is mediated by suppression of the apoptosis inhibitor Apollon. Ann Thorac Surg 2008;86:109-14.
34. Fuchs D, Christofferson R, Stridsberg M, Lindhagen E, Azarbayjani F. Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. J Transl Med 2009;7:16.
35. Henriksson KC, Almgren MA, Thurlow R, Varki NM, Chang CL. A fluorescent orthotopic mouse model for reliable measurement and genetic modulation of human neuroblastoma metastasis. Clin Exp Metast 2004;21:563-70.
36. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (New York, NY) 1984; 224:1121-4. (Pubitemid 14106392)
37. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13.
38. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/ Sp3. Proc Natl Acad Sci U S A 2001;98:4510-5. (Pubitemid 32295007)
39. Gartel AL. A new mode of transcriptional repression by c-myc: methylation. Oncogene 2006;25:1989-90.
40. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PloS One 2009;4:e8154.
41. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 2010;29:5957-68.
42. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, et al. A SP1/ MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 2011;71:404-12.
43. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-6. (Pubitemid 20225687)
44. Fotsis T, Breit S, Lutz W, R€ossler J, Hatzi E, Schwab M, et al. Downregulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 1999;263:757-64. (Pubitemid 29361948)
45. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17:339-46. (Pubitemid 28383010)
46. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Instit 2009;101:1562-74.
47. Alam G, Cui H, Shi H, Yang L, Ding J, Mao L, et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 2009;175:856-66.
48. Jackson A, Linsley PS. The therapeutic potential of microRNA modulation. Discov Med 2010;9:311-8.
49. Seto AG. The road toward microRNA therapeutics. Int J Biochem Cell Biol 2010;42:1298-305.
50. Website POO [Internet]. Oncogenomics Data center; host site for genomic profiling data of pediatric cancers [cited 2010 Nov]. Available from: http://pob.abcc.ncifcrf.gov/cgi-bin/JK.